Andrey Espinoza, MD
Cardiovascular Disease · Flemington, NJNPI 1255384897
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Philips North America LLC accounts for 65.6% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2023 at $20,623 and has fallen 99.3% since, to $144 in 2025. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 207 payments — averaging $286.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$39K
- Medtronic$8K
- Johnson & Johnson$7K
- Janssen Scientific Affairs, LLC$4K
- AstraZeneca$526
- Senseonics, Incorporated$258
- plus $2K from 31 others
Across 57 payments — averaging $8977.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cleerly, Inc.$457K
- American Regent$43K
- Amgen$11K
- Merck$450
What the payments were for
- Consulting fees$23,20039%
- Speaking & faculty fees$21,59836%
- Travel & lodging$10,77418%
- Food & beverage$3,5896%
- Education$1210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 41 | $38,874 |
| Medtronic(2 entities) | 26 | $7,593 |
| Johnson & Johnson | 42 | $6,607 |
| Janssen Scientific Affairs, LLC | 1 | $3,500 |
| AstraZeneca | 9 | $526 |
| Senseonics, Incorporated | 3 | $258 |
| Endologix LLC | 1 | $243 |
| Reflow Medical Inc | 1 | $174 |
| Boston Scientific | 3 | $154 |
| Abbott | 7 | $137 |
| Esperion Therapeutics, Inc. | 10 | $135 |
| Novartis | 7 | $112 |
| Amgen | 7 | $106 |
| Cordis US CORP. | 2 | $94 |
| Regeneron Healthcare Solutions, Inc. | 6 | $84 |
| Pfizer | 6 | $75 |
| Merck | 3 | $65 |
| Cardiva Medical, Inc. | 2 | $60 |
| Sanofi-aventis U.S. LLC | 4 | $57 |
| Irhythm Technologies, Inc. | 1 | $44 |
| Amarin Pharma, Inc. | 3 | $43 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $39 |
| Cardiovascular Systems Inc. | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Edwards Lifesciences | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Boehringer Ingelheim | 2 | $23 |
| Terumo Medical Corporation | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Organogenesis Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Bridgebio Pharma, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $14 |
| Bard Peripheral Vascular, Inc. | 1 | $14 |
| Cashflow Solutions, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (9520) IGT Devices Undivided$15,024
- US Und$9,947
- XARELTO$9,833
- RESOLUTE ONYX$7,219
- IGT D Peripheral$3,200
- IVUS Systems$3,200
- IGT Devices Und$3,200
- (8334) Image Guided Therapy Devices _ Peripheral$3,200
- FARXIGA$360
- IGT Systems Und$258
- Torus Stent Graft System$243
- ENDOCROSS Device$243
- Eversense$233
- (8977) Zenition 70$132
- Watchman$123
- (4067) Tack Endo Sys BTK$118
How this compares
$59,282 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 633 | $769,260 |
| XareltoRivaroxaban | 182 | $214,715 |
| EntrestoSacubitril/Valsartan | 94 | $104,703 |
| Repatha SureclickEvolocumab | 91 | $94,778 |
| Praluent PenAlirocumab | 47 | $51,144 |
| BrilintaTicagrelor | 31 | $37,809 |
| JardianceEmpagliflozin | 43 | $37,428 |
| NexletolBempedoic Acid | 22 | $16,707 |
| NexlizetBempedoic Acid/Ezetimibe | 19 | $15,182 |
| Metoprolol Succinate | 718 | $11,258 |
| LivaloPitavastatin Calcium | 15 | $10,746 |
| Rosuvastatin Calcium | 744 | $9,354 |
| Repatha SyringeEvolocumab | 17 | $8,831 |
| Midodrine Hcl | 39 | $6,688 |
| ClopidogrelClopidogrel Bisulfate | 373 | $6,263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $75 | $769,260633 claims |
| Johnson & JohnsonXarelto | $6,607 | $214,715182 claims |
| NovartisEntresto | $112 | $104,70394 claims |
| AstraZenecaBrilinta | $526 | $37,80931 claims |
| Boehringer IngelheimJardiance | $23 | $37,42843 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $135 | $31,88941 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $27 | $10,74615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Flemington
- Austin KutscherFlemington$117K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.